News | Cardiovascular Clinical Studies | August 14, 2023

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

Esperion announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates on prevention and lipid lowering” at the 2023 ESC Congress

August 14, 2023 — Esperion announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates on prevention and lipid lowering” at the 2023 ESC Congress taking place August 25-28, 2023, in Amsterdam, Netherlands. 

Session Title: 

CLEAR Outcomes Total Events Analysis 

  

  

Date/Time: 

August 26, 2023: 1630 CEST 

Location: 

Hub Rembrandt 

Presenter: 

Stephen Nicholls, MBBS, PhD 

  

Victorian Heart Institute, Monash University - Melbourne, Australia 

  

  

AND 

  

  

  

Session Title: 

CLEAR Outcomes Analysis by Glycaemic Status 

Date/Time: 

August 26, 2023: 1700 CEST 

Location: 

Hub Rembrandt 

Presenter: 

Kausik K Ray, MD, FMedSci 

  

Imperial College London - London, United Kingdom of Great Britain & Northern Ireland 

  

  

CLEAR Cardiovascular Outcomes Trial 

CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL (bempedoic acid) Tablet and NEXLIZET (bempedoic acid and ezetimibe) Tablet. The CLEAR Program seeks to generate important clinical evidence on the safety and efficacy of bempedoic acid, a first in a class ATP citrate lyase inhibitor contained in NEXLETOL and NEXLIZET and its potential role in addressing additional critical unmet medical needs. More than 60,000 people will have participated in the program by the time of its completion. The CLEAR Program includes 5 label-enabling Phase III studies as well as other key Phase IV studies with the potential to reach more than 70 million people with or at risk for CVD based on elevated LDL-C.
 

Esperion discovers, develops, and commercializes innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work.  

For more information: esperion.com  

Related CLEAR content:  

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population  

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC  

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology  

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL (bempedoic acid) Meets Primary Endpoint  


Related Content

News | Cardiovascular Education

May 31, 2024 — In the United States there are over 8 million active athletes. Given the rapid expansion of sports ...

Home May 31, 2024
Home
News | Cardiovascular Education

April 25, 2024 —Heart-Valve-Surgery.com, a leading patient advocacy group for heart valve disease, with support from ...

Home April 25, 2024
Home
News | Cardiovascular Education

March 21, 2024 — The UCLA Department of Medicine has announced that Priscilla Hsue, MD will be joining as the chief of ...

Home March 21, 2024
Home
Feature | Cardiovascular Education | Christine Book

February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country ...

Home February 01, 2024
Home
News | Cardiovascular Education

January 15, 2024 — A public-private partnership Think Tank, scheduled for Feb. 29-March 1, will be presented by the ...

Home January 15, 2024
Home
News | Cardiovascular Education

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

Home December 04, 2023
Home
News | Cardiovascular Education

October 5, 2023 — The 2023 American College of Cardiology (ACC) Quality Summit kicks off on October 11-13 in Orlando ...

Home October 05, 2023
Home
News | Cardiovascular Education

DAIC’s award-winning editorial team delivers industry trends and technology information to the professionals who make ...

Home August 16, 2023
Home
Feature | Cardiovascular Education | Christine Book

May 4, 2023 — A new book on a broad collection of cases, led by a team of investigators from the Smidt Heart Institute ...

Home May 04, 2023
Home
News | Cardiovascular Education

April 10, 2023 — Viatris Inc., a global healthcare company, and the American College of Cardiology (ACC) today released ...

Home April 10, 2023
Home
Subscribe Now